Riat El Khair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Riat El Khair has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Lalu Muhammad Irham
Universitas Ahmad Dahlan
7 shared publications - Wirawan Adikusuma
Research Center for Computing, Research Organization for Electronics and Informatics, National Research and Innovation Agency, Cibinong, Indonesia
7 shared publications - Danang Prasetyaning Amukti
Alma Ata University, Yogyakarta, Indonesia
6 shared publications - Rahmat Dani Satria
Department of Clinical Pathology and aboratory Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia
6 shared publications - Rockie Chong
Department of Chemistry and Biochemistry, University of California, Los Angeles, USA
5 shared publications - Rizky Gustinanda
Faculty of Halal Industry, University Nahdatul Ulama Yogyakarta, Indonesia
4 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 57 (1) , 49-57
Gene variants that may enhance the effectiveness of non-Hodgkin lymphoma therapy: Genomic and bioinformatics approaches
Background/Aim: Non-Hodgkin lymphoma (NHL) is a cancer of the lymphatic system with a high incidence rate globally. Patient responses to therapies such as chemotherapy and immunotherapy often vary, which is thought to be related to individual genetic differences. The development of genomic and bioinformatic technologies allows the identification of gene variants that play a role in the effectiveness of therapy, thus opening up opportunities for personalised treatment of NHL. This study aimed to identify genetic variants that have the potential to improve the effectiveness of therapy in NHL patients.Methods: This study used a bioinformatics approach to analyse genetic and clinical data available in several database sources, including PharmGKB, HaploReg v4.2, GTEx Portal and Ensembl.Results: This study identified two significant genetic variants, rs396991 in the FCGR3A gene and rs3957357 in the GSTA1 gene, that play a role in improving the effectiveness of NHL therapy. The rs396991 variant showed increased affinity for IgG1 and effectiveness of antibody-dependent cellular cytotoxicity (ADCC) mechanism in rituximab therapy. Meanwhile, the rs3957357 variant in GSTA1 was associated with better event-free survival in patients receiving R-CHOP chemotherapy. High expression of FCGR3A gene in immune tissues and GSTA1 gene in liver also supports their biological roles in therapy response.Conclusions: Genetic variations in FCGR3A (rs396991) and GSTA1 (rs3957357) have potential as predictive biomarkers of R-CHOP therapy effectiveness in NHL patients. These findings support the application of genetic analysis as a basis for more personalised and effective therapeutic strategies in the treatment of NHL.
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 57 (1) , 49-57
Open AccessGene variants that may enhance the effectiveness of non-Hodgkin lymphoma therapy: Genomic and bioinformatics approaches
Background/Aim: Non-Hodgkin lymphoma (NHL) is a cancer of the lymphatic system with a high incidence rate globally. Patient responses to therapies such as chemotherapy and immunotherapy often vary, which is thought to be related to individual genetic differences. The development of genomic and bioinformatic technologies allows the identification of gene variants that play a role in the effectiveness of therapy, thus opening up opportunities for personalised treatment of NHL. This study aimed to identify genetic variants that have the potential to improve the effectiveness of therapy in NHL patients.Methods: This study used a bioinformatics approach to analyse genetic and clinical data available in several database sources, including PharmGKB, HaploReg v4.2, GTEx Portal and Ensembl.Results: This study identified two significant genetic variants, rs396991 in the FCGR3A gene and rs3957357 in the GSTA1 gene, that play a role in improving the effectiveness of NHL therapy. The rs396991 variant showed increased affinity for IgG1 and effectiveness of antibody-dependent cellular cytotoxicity (ADCC) mechanism in rituximab therapy. Meanwhile, the rs3957357 variant in GSTA1 was associated with better event-free survival in patients receiving R-CHOP chemotherapy. High expression of FCGR3A gene in immune tissues and GSTA1 gene in liver also supports their biological roles in therapy response.Conclusions: Genetic variations in FCGR3A (rs396991) and GSTA1 (rs3957357) have potential as predictive biomarkers of R-CHOP therapy effectiveness in NHL patients. These findings support the application of genetic analysis as a basis for more personalised and effective therapeutic strategies in the treatment of NHL.
- Open Access
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 50-64
Gene variants that may cause adverse drug reactions in non-Hodgkin’s lymphoma therapy: a genomic and bioinformatics approach
Introduction. Chemotherapy remains a cornerstone treatment for most non-Hodgkin lymphoma (NHL) patients, yet it is frequently associated with significant adverse effects that compromise their quality of life. Emerging evidence highlights that genetic factors, particularly single nucleotide polymorphisms (SNPs), play a critical role in determining individual variability in treatment responses and susceptibility to drug-related complications.Aim of this study: to identify SNPs associated with chemotherapy-induced adverse events in NHL through advanced bioinformatics approaches, enabling personalized therapeutic strategies to mitigate risks.Material abd Methods. This study leveraged the PharmGKB database to identify SNPs associated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. SNPs meeting inclusion criteria (Level of Evidence 1A-3, pResults. This study identified 11 SNPs that may be important for hematological toxicity, liver damage, and nausea risk. These genes are SLC22A16, GSTP1, NAT2, ATM, ABCB1, CYP2B6, XRCC1, ERCC1, MUTYH PIK3R2, and PNPLA3. In terms of priority and risk, the most significant variants were rs738409 (PNPLA3), rs12210538 (SLC22A16), rs2229109 (ABCB1), and rs56022120 (PIK3R2). The distribution of SNP alleles is more common in European populations than in Asians or Africans.Conclusion. For the first time, we found SNPs that indicate an increase in drug side effects. These SNPs rs738409, rs12210538, rs2229109 and rs56022120 increase the severity of NHL patients during chemotherapy. In order to ensure that these biomarkers can be used in clinical practice and to support the creation of precision medicine strategies, additional clinical validation is needed.
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 50-64
Open AccessGene variants that may cause adverse drug reactions in non-Hodgkin’s lymphoma therapy: a genomic and bioinformatics approach
Introduction. Chemotherapy remains a cornerstone treatment for most non-Hodgkin lymphoma (NHL) patients, yet it is frequently associated with significant adverse effects that compromise their quality of life. Emerging evidence highlights that genetic factors, particularly single nucleotide polymorphisms (SNPs), play a critical role in determining individual variability in treatment responses and susceptibility to drug-related complications.Aim of this study: to identify SNPs associated with chemotherapy-induced adverse events in NHL through advanced bioinformatics approaches, enabling personalized therapeutic strategies to mitigate risks.Material abd Methods. This study leveraged the PharmGKB database to identify SNPs associated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. SNPs meeting inclusion criteria (Level of Evidence 1A-3, pResults. This study identified 11 SNPs that may be important for hematological toxicity, liver damage, and nausea risk. These genes are SLC22A16, GSTP1, NAT2, ATM, ABCB1, CYP2B6, XRCC1, ERCC1, MUTYH PIK3R2, and PNPLA3. In terms of priority and risk, the most significant variants were rs738409 (PNPLA3), rs12210538 (SLC22A16), rs2229109 (ABCB1), and rs56022120 (PIK3R2). The distribution of SNP alleles is more common in European populations than in Asians or Africans.Conclusion. For the first time, we found SNPs that indicate an increase in drug side effects. These SNPs rs738409, rs12210538, rs2229109 and rs56022120 increase the severity of NHL patients during chemotherapy. In order to ensure that these biomarkers can be used in clinical practice and to support the creation of precision medicine strategies, additional clinical validation is needed.
- Open Access
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 56 (6) , 1217-1227
Trend of non-Hodgkin lymphoma research using a genomics-based approach: A bibliometric analysis from 1985-2024
Non-Hodgkin lymphoma (NHL) is a group of malignant lymphoproliferative diseases that vary in histology, molecular biology, clinical presentation and prognosis. Genetic mutations and dysregulation play a critical role in its pathogenesis and classification. Understanding the publication landscape of NHL-related genetic studies is essential to map research trends and identify key contributors. This article aimed to conduct a bibliometric analysis of research trends in the field of NHL and related genomic studies. This study used bibliometric analysis using VOSviewer 1.6.16 and Biblioshiny (R tool) to visualise and interpret global publication trends. Data were collected from the Scopus database using keywords related to "Non-Hodgkin's Lymphoma" and "Genomic", covering publications from 1985 to 2024. The analysis identified that the United States dominates in citation contributions with a total of 7,328 citations, indicating strong research output and impact. The most productive journal was Blood with 57 publications, followed by Leukemia and the British Journal of Haematology. The most cited article was by Gaidano G (1991), published in PNAS, with a total of 906 citations. Co-authorship and keyword analysis revealed active international collaboration and emerging areas of focus such as BCL2, DLBCL and MYC. The trend in publications of NHL-related genetic research showed a significant increase over the years, with the US playing a dominant role in terms of output and citation impact. These findings highlight the growing interest and development in NHL genetic studies, which supports international collaboration and ongoing exploration of molecular targets.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 56 (6) , 1217-1227
Open AccessTrend of non-Hodgkin lymphoma research using a genomics-based approach: A bibliometric analysis from 1985-2024
Non-Hodgkin lymphoma (NHL) is a group of malignant lymphoproliferative diseases that vary in histology, molecular biology, clinical presentation and prognosis. Genetic mutations and dysregulation play a critical role in its pathogenesis and classification. Understanding the publication landscape of NHL-related genetic studies is essential to map research trends and identify key contributors. This article aimed to conduct a bibliometric analysis of research trends in the field of NHL and related genomic studies. This study used bibliometric analysis using VOSviewer 1.6.16 and Biblioshiny (R tool) to visualise and interpret global publication trends. Data were collected from the Scopus database using keywords related to "Non-Hodgkin's Lymphoma" and "Genomic", covering publications from 1985 to 2024. The analysis identified that the United States dominates in citation contributions with a total of 7,328 citations, indicating strong research output and impact. The most productive journal was Blood with 57 publications, followed by Leukemia and the British Journal of Haematology. The most cited article was by Gaidano G (1991), published in PNAS, with a total of 906 citations. Co-authorship and keyword analysis revealed active international collaboration and emerging areas of focus such as BCL2, DLBCL and MYC. The trend in publications of NHL-related genetic research showed a significant increase over the years, with the US playing a dominant role in terms of output and citation impact. These findings highlight the growing interest and development in NHL genetic studies, which supports international collaboration and ongoing exploration of molecular targets.
- Open Access
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 56 (2) , 395-404
International developments in atherosclerosis disease research using precision medicine (1994-2024): A bibliometric analysis
Cardiovascular disease has risen to the leading cause of global death. Atherosclerosis is an important contributor to the development of cardiovascular disease, which is involved in the formation of atheromatous plaques on the walls of arteries, resulting in arterial stenosis. In the past two decades, the treatment approach has shifted from conventional methods to precision medicine, which aims to tailor medical interventions based on individual patient characteristics, including genetic information, biomarkers and environmental factors. A literature search of precision medicine research on atherosclerosis from 1994 to 2024 was conducted using the Scopus database. VOSViewer v.1.6.16 and Biblioshiny software programs were used to perform bibliometric analysis. Between 1994 and 2024, 482 documents were published from 299 different sources, with an average document age of 3.68 years and an average of 24.52 citations per document. The total number of authors involved was 3.141, with 40 of them writing the documents individually. Collaboration between authors was very prominent, with an average of 7.89 authors per document and 29.46 % of the documents involving international collaboration. The types of documents published were also diverse, including 187 articles, 1 book, 15 book chapters, 11 conference papers, 33 editorials, 1 erratum, 4 letters, 8 notes, 219 reviews and 3 short surveys. Global trends in precision medicine for atherosclerosis research from 1994 to 2024 showed that the field has undergone significant development. Precision medicine has great potential to improve the care of patients with atherosclerosis through a more personalised and data-driven approach. To maximise its benefits globally, international collaboration, investment in technology and education are needed to overcome existing barriers. Thus, precision medicine can bring significant changes to the research and treatment of atherosclerosis in the future.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 56 (2) , 395-404
Open AccessInternational developments in atherosclerosis disease research using precision medicine (1994-2024): A bibliometric analysis
Cardiovascular disease has risen to the leading cause of global death. Atherosclerosis is an important contributor to the development of cardiovascular disease, which is involved in the formation of atheromatous plaques on the walls of arteries, resulting in arterial stenosis. In the past two decades, the treatment approach has shifted from conventional methods to precision medicine, which aims to tailor medical interventions based on individual patient characteristics, including genetic information, biomarkers and environmental factors. A literature search of precision medicine research on atherosclerosis from 1994 to 2024 was conducted using the Scopus database. VOSViewer v.1.6.16 and Biblioshiny software programs were used to perform bibliometric analysis. Between 1994 and 2024, 482 documents were published from 299 different sources, with an average document age of 3.68 years and an average of 24.52 citations per document. The total number of authors involved was 3.141, with 40 of them writing the documents individually. Collaboration between authors was very prominent, with an average of 7.89 authors per document and 29.46 % of the documents involving international collaboration. The types of documents published were also diverse, including 187 articles, 1 book, 15 book chapters, 11 conference papers, 33 editorials, 1 erratum, 4 letters, 8 notes, 219 reviews and 3 short surveys. Global trends in precision medicine for atherosclerosis research from 1994 to 2024 showed that the field has undergone significant development. Precision medicine has great potential to improve the care of patients with atherosclerosis through a more personalised and data-driven approach. To maximise its benefits globally, international collaboration, investment in technology and education are needed to overcome existing barriers. Thus, precision medicine can bring significant changes to the research and treatment of atherosclerosis in the future.
- Open Access
- 31 December 2024
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 30 (4) , 108-120
Genomic variants and epidemiology of atherosclerosis – worldwide correlation analysis and utilization of atherosclerosis gene variants for identification of drug target candidates with bioinformatics approach
Introduction: Atherosclerosis (AS) is a major risk factor for cardiovascular disease (CVD), which is the leading cause of death worldwide. Genetic factors are an integral factor in the cause of AS. This study aims to correlate epidemiological data, prevalence and mortality of AS worldwide with Single Nucleotide Polymorphisms (SNPs) associated with susceptibility and severity in different populations. Hence, utilized the gene variants to discover potential drug targets using bioinformatics. Material and methods: This study used a secondary data-driven bioinformatics approach to analyze the correlation between genetic variants associated with AS and epidemiological data from different regions of the world. Genetic data were obtained from the GWAS Catalog, while epidemiological data were collected from WHO and Our World in Data. The analysis was performed by fi ltering SNPs based on several criteria, namely the missense variant category, signifi cant p-value < 10-5, and prediction of variant impact using PolyPhen (Possibly Damaging) and SIFT (Deleterious). The correlation between allele frequency and AS prevalence and mortality was analyzed using the Pearson test. Results: The results of the study obtained three missense variants rs11466653 in TLR10, rs2296172 in MACF1 and rs6025 in F5. at rs11466653 has a role in the pathogenesis of AS with analysis using SNPnexus which shows the possibility of damaging (PolyPhen) and deleterious (SIFT) properties in addition to the results of the correlation test signifi cant to the prevalence and mortality of global AS (p < 0.05). Due to the challenge of drugging all potential target genes, our study was only able to identify the F5 gene as a viable target. The results of the identifi cation of candidate drugs targeting the F5 gene indicate that copper has the potential to be used in the treatment of AS. This assessment is based on a scoring analysis where the drug obtained a score of 6 indicating excellent quality or suitability in the context of drug repurposing for AS treatment. Conclusion: The fi ndings in this study will encourage efforts to improve AS diagnosis and early treatment, as well as increase public awareness of the importance of genetic factors and lifestyle in preventing this disease. This study can also be a reference for further research focusing on genetic intervention and development of personalized therapy for AS. Therefore it can provide broader benefi ts for global public health.
- 31 December 2024
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 30 (4) , 108-120
Open AccessGenomic variants and epidemiology of atherosclerosis – worldwide correlation analysis and utilization of atherosclerosis gene variants for identification of drug target candidates with bioinformatics approach
Introduction: Atherosclerosis (AS) is a major risk factor for cardiovascular disease (CVD), which is the leading cause of death worldwide. Genetic factors are an integral factor in the cause of AS. This study aims to correlate epidemiological data, prevalence and mortality of AS worldwide with Single Nucleotide Polymorphisms (SNPs) associated with susceptibility and severity in different populations. Hence, utilized the gene variants to discover potential drug targets using bioinformatics. Material and methods: This study used a secondary data-driven bioinformatics approach to analyze the correlation between genetic variants associated with AS and epidemiological data from different regions of the world. Genetic data were obtained from the GWAS Catalog, while epidemiological data were collected from WHO and Our World in Data. The analysis was performed by fi ltering SNPs based on several criteria, namely the missense variant category, signifi cant p-value < 10-5, and prediction of variant impact using PolyPhen (Possibly Damaging) and SIFT (Deleterious). The correlation between allele frequency and AS prevalence and mortality was analyzed using the Pearson test. Results: The results of the study obtained three missense variants rs11466653 in TLR10, rs2296172 in MACF1 and rs6025 in F5. at rs11466653 has a role in the pathogenesis of AS with analysis using SNPnexus which shows the possibility of damaging (PolyPhen) and deleterious (SIFT) properties in addition to the results of the correlation test signifi cant to the prevalence and mortality of global AS (p < 0.05). Due to the challenge of drugging all potential target genes, our study was only able to identify the F5 gene as a viable target. The results of the identifi cation of candidate drugs targeting the F5 gene indicate that copper has the potential to be used in the treatment of AS. This assessment is based on a scoring analysis where the drug obtained a score of 6 indicating excellent quality or suitability in the context of drug repurposing for AS treatment. Conclusion: The fi ndings in this study will encourage efforts to improve AS diagnosis and early treatment, as well as increase public awareness of the importance of genetic factors and lifestyle in preventing this disease. This study can also be a reference for further research focusing on genetic intervention and development of personalized therapy for AS. Therefore it can provide broader benefi ts for global public health.
- Open Access
- 31 December 2024
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 30 (4) , 40-48
Atherosclerosis research in the genomic era: global trends from 1983 to 2024
Atherosclerosis (AS) a chronic cardiovascular disease, poses a major threat to human health and remains one of the leading causes of mortality among the elderly. Genetic factors have long been recognized as contributors to the predisposition to heart and vascular diseases, with several studies suggesting that specifi c genetic variants may infl uence AS risk. This study employs a bibliometric analysis to explore scientifi c literature related to AS throughusing genomic approaches, base on Scopus data spanning 1983 to 2024. A total of 1,702 studies related to AS research employing genomic approaches were identifi ed, comprising 1,137 research articles, 445 review articles, and 120 documents in other categories. The fi ndings reveal a marked rise in interest in regarding genomic approaches to AS, particularly since 2017, with the United States, China, and the United Kingdom leading in research output. International collaborations are also prevalent, with the United States contributing the most publications. Although contributions from Indonesian authors remain limited, there is signifi cant potential for future involvement. Notably, the most cited article, authored by Naghavi et al. in 2003, focusing on genomics in AS. Overall, the bibliometric analysis provides valuable insights into research trends and advancements in the study of atherosclerosis through genomic approaches.
- 31 December 2024
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 30 (4) , 40-48
Open AccessAtherosclerosis research in the genomic era: global trends from 1983 to 2024
Atherosclerosis (AS) a chronic cardiovascular disease, poses a major threat to human health and remains one of the leading causes of mortality among the elderly. Genetic factors have long been recognized as contributors to the predisposition to heart and vascular diseases, with several studies suggesting that specifi c genetic variants may infl uence AS risk. This study employs a bibliometric analysis to explore scientifi c literature related to AS throughusing genomic approaches, base on Scopus data spanning 1983 to 2024. A total of 1,702 studies related to AS research employing genomic approaches were identifi ed, comprising 1,137 research articles, 445 review articles, and 120 documents in other categories. The fi ndings reveal a marked rise in interest in regarding genomic approaches to AS, particularly since 2017, with the United States, China, and the United Kingdom leading in research output. International collaborations are also prevalent, with the United States contributing the most publications. Although contributions from Indonesian authors remain limited, there is signifi cant potential for future involvement. Notably, the most cited article, authored by Naghavi et al. in 2003, focusing on genomics in AS. Overall, the bibliometric analysis provides valuable insights into research trends and advancements in the study of atherosclerosis through genomic approaches.
- Open Access
- 14 February 2024
- Published by Veterinary World in International Journal of One Health
Distribution of antimicrobial resistance genes of methicillin-resistant Staphylococcus aureus isolated from animals and humans in Yogyakarta Indonesia
Background and Aim: Methicillin-resistant Staphylococcus aureus (MRSA) has been known as a highly pathogenic bacteria in animals and humans, which is still becoming a global health issue. The prevalence of MRSA infection continues to increase worldwide and has become a global concern as a dangerous zoonotic disease. The World Health Organization estimates that by 2050 MRSA will be the leading cause of death. This study aimed to estimate the prevalence of MRSA in S. aureus isolates of veterinary and human origin in Yogyakarta, Indonesia. Materials and Methods: A total of 42 cases of S. aureus infection were examined in this study, consisting of nine isolates from cattle, five from goat, and 28 from human. All isolates were confirmed as S. aureus based on bacterial culture and detection of 23S rRNA and thermonuclease nuc gene by polymerase chain reaction (PCR). Results: Among 42 isolates, 35 isolates (83.3%) were identified as MRSA by PCR positive of mecA gene encoding methicillin resistance. Most MRSA strains were found in human isolates (100%), followed by cattle isolates (55.5%) and goats (40%). All MRSA strains were also multi-resistant to penicillin (blaZ gene) and tetracycline (tetK, and tetM genes) with a prevalence of about 98%. Conclusion: MRSA prevalence in humans and animals has increased significantly in Yogyakarta, Indonesia, compared to the previous study. The antimicrobial resistance pattern of MRSA animal isolates tends to be similar to humans and, thus, raises public health concerns about MRSA zoonotic spread. Keywords: animal, antimicrobial resistance, human, methicillin-resistant Staphylococcus aureus, Staphylococcus aureus.
- 14 February 2024
- Published by Veterinary World in International Journal of One Health
Open AccessDistribution of antimicrobial resistance genes of methicillin-resistant Staphylococcus aureus isolated from animals and humans in Yogyakarta Indonesia
Background and Aim: Methicillin-resistant Staphylococcus aureus (MRSA) has been known as a highly pathogenic bacteria in animals and humans, which is still becoming a global health issue. The prevalence of MRSA infection continues to increase worldwide and has become a global concern as a dangerous zoonotic disease. The World Health Organization estimates that by 2050 MRSA will be the leading cause of death. This study aimed to estimate the prevalence of MRSA in S. aureus isolates of veterinary and human origin in Yogyakarta, Indonesia. Materials and Methods: A total of 42 cases of S. aureus infection were examined in this study, consisting of nine isolates from cattle, five from goat, and 28 from human. All isolates were confirmed as S. aureus based on bacterial culture and detection of 23S rRNA and thermonuclease nuc gene by polymerase chain reaction (PCR). Results: Among 42 isolates, 35 isolates (83.3%) were identified as MRSA by PCR positive of mecA gene encoding methicillin resistance. Most MRSA strains were found in human isolates (100%), followed by cattle isolates (55.5%) and goats (40%). All MRSA strains were also multi-resistant to penicillin (blaZ gene) and tetracycline (tetK, and tetM genes) with a prevalence of about 98%. Conclusion: MRSA prevalence in humans and animals has increased significantly in Yogyakarta, Indonesia, compared to the previous study. The antimicrobial resistance pattern of MRSA animal isolates tends to be similar to humans and, thus, raises public health concerns about MRSA zoonotic spread. Keywords: animal, antimicrobial resistance, human, methicillin-resistant Staphylococcus aureus, Staphylococcus aureus.
- Open Access
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 55 (6) , 787-794
Healthy connections: Crafting compelling healthcare marketing strategies
Due to the importance of healthcare on both an individual and public level, the efficient functionality of the healthcare system is a fundamental component of society's overall well-being. The primary purpose of this research was to assess how academic contributions to healthcare marketing investigations have evolved over time. The paper delved into various aspects from 2015 to 2024, including publishing trends, core journals, authorship patterns, institutional affiliations, nation-wise contributions, theme distributions, author collaborations and keywords. Data was collected from the Scopus database by using appropriate keywords. The collected dataset underwent meticulous analysis and visualisation using the VOSviewer software. This analytical approach facilitated the identification of significant bibliometric metrics, enabling a deeper understanding of the dynamics and peculiarities of healthcare marketing research throughout the specified period. The most fruitful affiliation or institutional source for healthcare marketing was University Sains Malaysia. Top 5 most productive authors contributing to the field of healthcare marketing were Bellio et al, Buccoliero et al, Djakeli et al, Ghinita et al and Harrison et al. The United States was the nation that produces the greatest number of scientific articles related to healthcare marketing. The most important journal for healthcare marketing was International Journal of Pharmaceutical and Healthcare Marketing. The most common subjects in healthcare marketing were business, management and accounting. With twenty-one publications, the number of international scholarly publications on healthcare marketing reached a peak in 2023. Eleven writers were closely associated with the ownership of two or more documents. There were 24 keywords with a significant human correlation.
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 55 (6) , 787-794
Open AccessHealthy connections: Crafting compelling healthcare marketing strategies
Due to the importance of healthcare on both an individual and public level, the efficient functionality of the healthcare system is a fundamental component of society's overall well-being. The primary purpose of this research was to assess how academic contributions to healthcare marketing investigations have evolved over time. The paper delved into various aspects from 2015 to 2024, including publishing trends, core journals, authorship patterns, institutional affiliations, nation-wise contributions, theme distributions, author collaborations and keywords. Data was collected from the Scopus database by using appropriate keywords. The collected dataset underwent meticulous analysis and visualisation using the VOSviewer software. This analytical approach facilitated the identification of significant bibliometric metrics, enabling a deeper understanding of the dynamics and peculiarities of healthcare marketing research throughout the specified period. The most fruitful affiliation or institutional source for healthcare marketing was University Sains Malaysia. Top 5 most productive authors contributing to the field of healthcare marketing were Bellio et al, Buccoliero et al, Djakeli et al, Ghinita et al and Harrison et al. The United States was the nation that produces the greatest number of scientific articles related to healthcare marketing. The most important journal for healthcare marketing was International Journal of Pharmaceutical and Healthcare Marketing. The most common subjects in healthcare marketing were business, management and accounting. With twenty-one publications, the number of international scholarly publications on healthcare marketing reached a peak in 2023. Eleven writers were closely associated with the ownership of two or more documents. There were 24 keywords with a significant human correlation.
- Open Access
- 30 September 2023
- Published by Korea Genome Organization in Genomics & Informatics
- Vol. 21 (3) , e31
Identification of druggable genes for multiple myeloma based on genomic information
Multiple myeloma (MM) is a hematological malignancy. It is widely believed that genetic factors play a significant role in the development of MM, as investigated in numerous studies. However, the application of genomic information for clinical purposes, including diagnostic and prognostic biomarkers, remains largely confined to research. In this study, we utilized genetic information from the Genomic-Driven Clinical Implementation for Multiple Myeloma database, which is dedicated to clinical trial studies on MM. This genetic information was sourced from the genome-wide association studies catalog database. We prioritized genes with the potential to cause MM based on established annotations, as well as biological risk genes for MM, as potential drug target candidates. The DrugBank database was employed to identify drug candidates targeting these genes. Our research led to the discovery of 14 MM biological risk genes and the identification of 10 drugs that target three of these genes. Notably, only one of these 10 drugs, panobinostat, has been approved for use in MM. The two most promising genes, calcium signal-modulating cyclophilin ligand (CAMLG) and histone deacetylase 2 (HDAC2), were targeted by four drugs (cyclosporine, belinostat, vorinostat, and romidepsin), all of which have clinical evidence supporting their use in the treatment of MM. Interestingly, five of the 10 drugs have been approved for other indications than MM, but they may also be effective in treating MM. Therefore, this study aimed to clarify the genomic variants involved in the pathogenesis of MM and highlight the potential benefits of these genomic variants in drug discovery.
- 30 September 2023
- Published by Korea Genome Organization in Genomics & Informatics
- Vol. 21 (3) , e31
Open AccessIdentification of druggable genes for multiple myeloma based on genomic information
Multiple myeloma (MM) is a hematological malignancy. It is widely believed that genetic factors play a significant role in the development of MM, as investigated in numerous studies. However, the application of genomic information for clinical purposes, including diagnostic and prognostic biomarkers, remains largely confined to research. In this study, we utilized genetic information from the Genomic-Driven Clinical Implementation for Multiple Myeloma database, which is dedicated to clinical trial studies on MM. This genetic information was sourced from the genome-wide association studies catalog database. We prioritized genes with the potential to cause MM based on established annotations, as well as biological risk genes for MM, as potential drug target candidates. The DrugBank database was employed to identify drug candidates targeting these genes. Our research led to the discovery of 14 MM biological risk genes and the identification of 10 drugs that target three of these genes. Notably, only one of these 10 drugs, panobinostat, has been approved for use in MM. The two most promising genes, calcium signal-modulating cyclophilin ligand (CAMLG) and histone deacetylase 2 (HDAC2), were targeted by four drugs (cyclosporine, belinostat, vorinostat, and romidepsin), all of which have clinical evidence supporting their use in the treatment of MM. Interestingly, five of the 10 drugs have been approved for other indications than MM, but they may also be effective in treating MM. Therefore, this study aimed to clarify the genomic variants involved in the pathogenesis of MM and highlight the potential benefits of these genomic variants in drug discovery.
- Open Access
- 20 September 2023
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 17 (9) , e0011575
The seroprevalence of anti-Histoplasma capsulatum IgG antibody among pulmonary tuberculosis patients in seven referral tuberculosis hospitals in Indonesia
Histoplasma capsulatum exposure is rarely suspected in Indonesia. Pulmonary histoplasmosis can occur simultaneously with pulmonary tuberculosis (TB) or as an alternative diagnosis in clinically-diagnosed TB patients with no microbiological evidence of TB. This study aimed to determine the seroprevalence of anti-H. capsulatum IgG antibody among pulmonary TB patients. This was a sub-study of 306 participants from a prospective cohort pulmonary TB study conducted at seven TB referral hospitals in Indonesia. The study population was presumptive pulmonary TB adult patients who underwent microbiological TB examinations and were categorized as drug-sensitive (DS), drug-resistant (DR), and clinically-diagnosed TB. Anti-H. capsulatum IgG antibody levels at baseline were measured using MVista Histoplasma Ab enzyme immunoassays. Data were summarized using descriptive statistics. Bivariate and multivariate logistic regression analysis were performed to assess factors associated with anti-H. capsulatum IgG antibody positive result. 12.7% (39/306) of pulmonary TB patients were positive for anti-H. capsulatum IgG antibodies (DR-TB patients (15.9%, 18/114), DS-TB (13.0%, 15/115), and clinically-diagnosed TB (7.8%, 6/77)). The median unit value of anti-H. capsulatum IgG antibody for all positive samples was 15.7 (IQR 10.2–28.9) EU. This median unit value was higher in clinically-diagnosed TB patients compared to DS-TB or DR-TB patients (38.1 (IQR 25.6–46.6) EU, 19.7 (IQR 12.3–28.9) EU, and 10.9 (IQR 9.2–15.4), respectively). There were 10 patients (3.3%) with anti-H. capsulatum IgG antibody levels above 30 EU. Factors associated with the anti-H. capsulatum IgG antibody positive result were malignancies (OR 4.88, 95% CI 1.09–21.69, p = 0.037) and cavitary lesions (OR 2.27, 95% CI 1.09–4.70, p = 0.028). Our results provide evidence of exposure to H. capsulatum among pulmonary TB patients in Indonesia. Further studies are needed to provide a comprehensive picture of this fungal disease in other populations and regions to enhance awareness among clinicians and public health officials. Histoplasma capsulatum exposure is rarely suspected in Indonesia, even though this fungal presence in the country has been reported since the 1930s. Pulmonary manifestations of histoplasmosis, especially chronic pulmonary histoplasmosis (CPH), resemble pulmonary tuberculosis (TB). It may be misdiagnosed as or be a co-infection with pulmonary TB. Since Indonesia is the second-highest TB-burdened country worldwide, it is imperative to capture histoplasmosis data among pulmonary TB patients. Our study provides evidence of H. capsulatum exposure by measuring anti-H. capsulatum IgG antibodies in both bacteriologically confirmed and clinically-diagnosed pulmonary TB patients at seven TB referral hospitals in Indonesia. We found 12.7% (39/306) of pulmonary TB patients were positive for anti-H. capsulatum IgG antibodies. We had a high suspicion of pulmonary histoplasmosis diagnosis in 10 of the 39 patients (six bacteriologically confirmed and four clinically-diagnosed TB) who were immunocompromised due to high IgG assay values (>30 EU). The utilization of other modalities, such as the Histoplasma antigen test, may support a histoplasmosis diagnosis. In our study, malignancies and cavitary lesions were associated with anti-H. capsulatum IgG antibody positive results. Our results bring much-needed preliminary data to guide policymakers regarding fungal infection in pulmonary TB patients and support further research on histoplasmosis in Indonesia.
- 20 September 2023
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 17 (9) , e0011575
Open AccessThe seroprevalence of anti-Histoplasma capsulatum IgG antibody among pulmonary tuberculosis patients in seven referral tuberculosis hospitals in Indonesia
Histoplasma capsulatum exposure is rarely suspected in Indonesia. Pulmonary histoplasmosis can occur simultaneously with pulmonary tuberculosis (TB) or as an alternative diagnosis in clinically-diagnosed TB patients with no microbiological evidence of TB. This study aimed to determine the seroprevalence of anti-H. capsulatum IgG antibody among pulmonary TB patients. This was a sub-study of 306 participants from a prospective cohort pulmonary TB study conducted at seven TB referral hospitals in Indonesia. The study population was presumptive pulmonary TB adult patients who underwent microbiological TB examinations and were categorized as drug-sensitive (DS), drug-resistant (DR), and clinically-diagnosed TB. Anti-H. capsulatum IgG antibody levels at baseline were measured using MVista Histoplasma Ab enzyme immunoassays. Data were summarized using descriptive statistics. Bivariate and multivariate logistic regression analysis were performed to assess factors associated with anti-H. capsulatum IgG antibody positive result. 12.7% (39/306) of pulmonary TB patients were positive for anti-H. capsulatum IgG antibodies (DR-TB patients (15.9%, 18/114), DS-TB (13.0%, 15/115), and clinically-diagnosed TB (7.8%, 6/77)). The median unit value of anti-H. capsulatum IgG antibody for all positive samples was 15.7 (IQR 10.2–28.9) EU. This median unit value was higher in clinically-diagnosed TB patients compared to DS-TB or DR-TB patients (38.1 (IQR 25.6–46.6) EU, 19.7 (IQR 12.3–28.9) EU, and 10.9 (IQR 9.2–15.4), respectively). There were 10 patients (3.3%) with anti-H. capsulatum IgG antibody levels above 30 EU. Factors associated with the anti-H. capsulatum IgG antibody positive result were malignancies (OR 4.88, 95% CI 1.09–21.69, p = 0.037) and cavitary lesions (OR 2.27, 95% CI 1.09–4.70, p = 0.028). Our results provide evidence of exposure to H. capsulatum among pulmonary TB patients in Indonesia. Further studies are needed to provide a comprehensive picture of this fungal disease in other populations and regions to enhance awareness among clinicians and public health officials. Histoplasma capsulatum exposure is rarely suspected in Indonesia, even though this fungal presence in the country has been reported since the 1930s. Pulmonary manifestations of histoplasmosis, especially chronic pulmonary histoplasmosis (CPH), resemble pulmonary tuberculosis (TB). It may be misdiagnosed as or be a co-infection with pulmonary TB. Since Indonesia is the second-highest TB-burdened country worldwide, it is imperative to capture histoplasmosis data among pulmonary TB patients. Our study provides evidence of H. capsulatum exposure by measuring anti-H. capsulatum IgG antibodies in both bacteriologically confirmed and clinically-diagnosed pulmonary TB patients at seven TB referral hospitals in Indonesia. We found 12.7% (39/306) of pulmonary TB patients were positive for anti-H. capsulatum IgG antibodies. We had a high suspicion of pulmonary histoplasmosis diagnosis in 10 of the 39 patients (six bacteriologically confirmed and four clinically-diagnosed TB) who were immunocompromised due to high IgG assay values (>30 EU). The utilization of other modalities, such as the Histoplasma antigen test, may support a histoplasmosis diagnosis. In our study, malignancies and cavitary lesions were associated with anti-H. capsulatum IgG antibody positive results. Our results bring much-needed preliminary data to guide policymakers regarding fungal infection in pulmonary TB patients and support further research on histoplasmosis in Indonesia.